Capital Advisors Inc. OK Has $7.65 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Capital Advisors Inc. OK lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) by 19.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 125,885 shares of the company’s stock after purchasing an additional 20,903 shares during the quarter. Capital Advisors Inc. OK’s holdings in CRISPR Therapeutics were worth $7,650,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Allworth Financial LP raised its position in shares of CRISPR Therapeutics by 21.0% during the second quarter. Allworth Financial LP now owns 737 shares of the company’s stock worth $45,000 after purchasing an additional 128 shares during the period. Antonetti Capital Management LLC raised its position in CRISPR Therapeutics by 16.1% in the 4th quarter. Antonetti Capital Management LLC now owns 1,190 shares of the company’s stock valued at $90,000 after buying an additional 165 shares during the last quarter. Stratos Wealth Partners LTD. raised its position in CRISPR Therapeutics by 5.6% in the 1st quarter. Stratos Wealth Partners LTD. now owns 3,992 shares of the company’s stock valued at $251,000 after buying an additional 211 shares during the last quarter. Bouvel Investment Partners LLC raised its position in CRISPR Therapeutics by 1.2% in the 2nd quarter. Bouvel Investment Partners LLC now owns 18,536 shares of the company’s stock valued at $1,126,000 after buying an additional 226 shares during the last quarter. Finally, Flagship Harbor Advisors LLC raised its position in CRISPR Therapeutics by 4.8% in the 1st quarter. Flagship Harbor Advisors LLC now owns 5,124 shares of the company’s stock valued at $322,000 after buying an additional 233 shares during the last quarter. 70.56% of the stock is owned by institutional investors and hedge funds.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 25,000 shares of the firm’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $75.91, for a total value of $1,897,750.00. Following the completion of the transaction, the chief executive officer now directly owns 290,279 shares of the company’s stock, valued at $22,035,078.89. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 75,000 shares of company stock worth $5,108,500 in the last ninety days. Company insiders own 5.30% of the company’s stock.

CRISPR Therapeutics Trading Down 2.7 %

CRISPR Therapeutics stock traded down $1.72 during midday trading on Friday, reaching $63.18. 87,266 shares of the stock traded hands, compared to its average volume of 1,057,316. CRISPR Therapeutics AG has a fifty-two week low of $42.51 and a fifty-two week high of $122.25. The firm has a fifty day moving average price of $72.80 and a two-hundred day moving average price of $65.48.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last posted its earnings results on Monday, August 8th. The company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($2.23) by ($0.17). The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $2.20 million. CRISPR Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,274.02%. The business’s revenue was down 100.0% on a year-over-year basis. During the same period in the prior year, the firm earned $9.44 earnings per share. Sell-side analysts expect that CRISPR Therapeutics AG will post -9.26 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on CRSP. SVB Leerink lowered their price target on CRISPR Therapeutics from $112.00 to $107.00 and set an “outperform” rating for the company in a research report on Monday, August 8th. Royal Bank of Canada cut their target price on CRISPR Therapeutics from $85.00 to $79.00 and set a “sector perform” rating for the company in a research note on Tuesday, August 9th. Barclays cut CRISPR Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $99.00 to $88.00 in a report on Tuesday, August 9th. Citigroup lifted their price objective on CRISPR Therapeutics from $53.00 to $83.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 2nd. Finally, Chardan Capital lowered their price objective on CRISPR Therapeutics from $164.00 to $154.00 and set a “buy” rating for the company in a research note on Tuesday, August 9th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. According to MarketBeat, CRISPR Therapeutics has an average rating of “Hold” and an average target price of $112.33.

CRISPR Therapeutics Profile

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Stories

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.